Member Info for Del77

My thoughts are that the BOD want to hold the AGM well before the 48 weeks results are released and therefore will not be in a position to discuss any progress on 7 June. I guess an RNS will be released in mid July with the initial headline results from the 48 week trial. D.

Tim is presenting for 5 minutes only at 12.20 tomorrow . Interestingly or co incidental , the next company to present is physiomics at 12.25 tomorrow. D.

As we get closer to the 48 week results , my gut feeling is that we will receive a bid from Sarepta for the dmd business and it will offered in sarepta shares as sarepta will wish to retain cash funds to continue research and development and provide funds to run the company. If sucessful at 48 weeks i do not believe sarepta would have sufficient funds required in cash to satisfy the Summit Board. Only my thoughts D.

Over11700 shares traded on nasdaq in the first 10 mins.Share price up 3.5% atUSD 14.25. Hope for a good finish before the weekend. D.

170k + buys and negligible movement in share price. Any ideas what is going on? GLA D.

Nice to see some sizeable share purchases go through later in the session. Hopefully in the US the share price will break through USD 14 this evening D.

I recall on previous occasions the share price has been marked lower in advance of positive news, that really moved the shares upwards. We will have to wait and see over the next few weeks. GLA D.

Good to see Summit up 3.9% in the US tonight. Will Sarepta bid for dmd arm of summ before the 48 week results This could become interesting in July No one likes doing deals in the summer holiday season so we could see the share rise in June on anticipation of the 48 week results and a potential buy out Gla D.

For info, Research grants funded by MRC, Medical Research Council, require final reports to be submitted within 90 days of the project end date. This is a standard clause for all research councils in the uk. If this logic is applied here ,the final report should be received by the end of May at the latest. D.

Potnak totally agree.. lets hope that is what Mr Parker was brought in for .”.lets package the science and sell it off to the highest bidder”... after all Tim is getting no younger, the business has no succession planning , the value needs to be in the science. After all i would assess these shares form a large part of Tims pension . Invested here now for 8 years... i hope the next six months provide an opportunity for a buyer to come forward as highlighted by Troth2. I would much prefer a t/o than another licence agreement . GLA D.

Possibly The accumulated tax losses i would have throught must be significant here (and therefore valuable). Could a business be looking to reverse its activities into Arian? D.

25p paid:) D

Andy Hopefully the great science continues to do Tims ‘talking’ . I agree , Parker and the brokers need to raise the profile of Sareum far more as Tim will never change. Tim is c 55 years old and i guess his Sareum shares are his pension. Parker is c 58 .For this reason i believe the guys must be looking to sell sareum sooner rather than later and ideally from Tims prospective, he would continue to work for acaquiring conpany. With CHK 1 milestone payments and then royalty payments and TYK2 possible licencing deal to come what not to like from a big pharma co. Afterall £200 m is really petty cash, especially as the work completed by Sierra significantly derisks an acquition of Sareum Invested for 9 years ... l think we are very close to the end game ...we will see how close next week:) D.

Interesting to note Sarepta have hit a a year high on the nasdaq and summit are up c 4.25% I can understand Summits increase after the rns today .. but why the increase in Sarepta...to a 52 week high. Anyone have any ideas? D.

Interesting to note the tight buy sell spread at present . I wonder if we are due any news? GLA. D

Chrisatrgd Is anyone aware given the expansion of the trials proposed by Sierra whether this will increase the amount of royalty payable in the short term Clearly this would be Subject to the terms of IP agreement which i assume are confidential, but the ‘reasonable man’ would assume we could now expect a higher stage payment given the increased scope of work proposed by Sierra in the short term D.

AppleMacMan Fair point. Sarepta still can make a bid at any time without access to ‘inside info’ especially given the 24 week data has been published in so much detail D.

On no volume.MM playing games? Will we see an rns at mid day or 7.00 tomorrow morning? D.

I agree with you Sarepta may take out Summ DMD , but i think it nay be sooner than later given Summits current low mkt value . It may help Sarepta manage relationships with U S health care providers and the FDA . If Sarepta wait for the successful 48week data the costs of taking Summ out would be multiples of what it would be now .. and even more if fast track status is granted in the US. The next 6 months will be very interesting. A further dose of patience is required. GLA . D.

Horse1 , perhaps there is a deal in the pipeline which may depend on the formal announcements made by Sierra last week and the lawyers need up to a couple of weeks to finalise a licencing agreement or even a takeover of Sareum, perhaps incorporating progress made by Sierra. Possibly wishful thinking on my behalf:) GLA D.